TaiMed Biologics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 491.78 million compared to TWD 563.01 million a year ago. Net loss was TWD 194.81 million compared to TWD 269.29 million a year ago.

Basic loss per share from continuing operations was TWD 0.77 compared to TWD 1.07 a year ago. Diluted loss per share from continuing operations was TWD 0.77 compared to TWD 1.07 a year ago.